TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29525738

Group type: COMPARATOR
Intervention: No label
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Generic disclaimer label
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Consequence label
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Informational label
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Graphic label
Number of subjects: 340
Study: 27775778

Group type: EXPERIMENTAL
Intervention: Glutamine-supplemented TPN
Number of subjects: 47

Group type: COMPARATOR
Intervention: Standard TPN
Number of subjects: 47
Study: 24462053

Group type: EXPERIMENTAL
Intervention: Preventive Home Visits (PHV)
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: Senior Meetings
Number of subjects: 459

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 459
Study: 22504855

Group type: EXPERIMENTAL
Intervention: Simulator training (SIM)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Crew resource management training (CRM)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 61
Study: 20570360

Group type: EXPERIMENTAL
Intervention: Subconjunctival lidocaine injection
Number of subjects: 65

Group type: COMPARATOR
Intervention: Sham injection
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Subconjunctival lidocaine injection (crossover group)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Sham injection (crossover group)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Preference for treatment
Number of subjects: 65
Study: 18505574

Group type: EXPERIMENTAL
Intervention: Physical activity study participants (240/560)
Number of subjects: 560

Group type: COMPARATOR
Intervention: Non-participants (320/560)
Number of subjects: 560
Study: 15647219

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 12628632

Group type: EXPERIMENTAL
Intervention: Recently dosed (n=21)
Number of subjects: 39

Group type: COMPARATOR
Intervention: 24 hr abstinent (n=18)
Number of subjects: 39
Study: 10593347

Group type: EXPERIMENTAL
Intervention: US 3 G: 1 g of stanol (ester form) per 8‐g serving of a US reformulation 3 times a day
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: US 2 G: 0.67 g of stanol (ester form) per 8‐g serving of a US reformulation 3 times a day
Number of subjects: 318

Group type: COMPARATOR
Intervention: Placebo spread
Number of subjects: 318
Study: 8915574

Group type: EXPERIMENTAL
Intervention: Increased levels of trkA receptors in astrocytes in the CA1 region of Alzheimer's disease hippocampi, associated with beta-amyloid-positive plaques.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High levels of truncated trkB receptors found in senile plaques in Alzheimer's disease brains.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Full-length trkB receptor expression in glial-like cells in the hippocampus of Alzheimer's disease brains.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Elevated trk receptor mRNA levels in Alzheimer's disease brains as indicated by in-situ hybridisation studies.
Number of subjects: 0
Study: 1910794

Group type: EXPERIMENTAL
Intervention: Alfentanil 0.01 mg/kg
Number of subjects: 80
Study: 7061727

Group type: EXPERIMENTAL
Intervention: Activated Charcoal (AC) 15 Gm
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Activated Charcoal + Sodium Sulfate (AC + SS) 15 Gm + 20 Gm
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (Water alone)
Number of subjects: 6
Study: 31237336

Group type: EXPERIMENTAL
Intervention: Fermented Flaxseed Cake (FFSC)
Number of subjects: 420

Group type: COMPARATOR
Intervention: Unfermented Flaxseed Cake (UFSC)
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Flaxseed Cake (FSC) supplementation
Number of subjects: 420
Study: 28527420

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC) followed by surgery with or without radiotherapy.
Number of subjects: 1553

Group type: COMPARATOR
Intervention: Triple negative breast cancer
Number of subjects: 1553

Group type: COMPARATOR
Intervention: HER2+ without trastuzumab
Number of subjects: 1553

Group type: COMPARATOR
Intervention: HER2+ with trastuzumab
Number of subjects: 1553

Group type: EXPERIMENTAL
Intervention: Patients with ≥4 pathologically positive nodes and lack of pathological response
Number of subjects: 1553
Study: 25204687

Group type: EXPERIMENTAL
Intervention: Subjective Memory Decline (SMD) at follow-up
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Subjective Memory Decline (SMD) at baseline
Number of subjects: 305

Group type: COMPARATOR
Intervention: Controlling for anxiety and depression symptomatology
Number of subjects: 305
Study: 23740422

Group type: EXPERIMENTAL
Intervention: Teriparatide (20 μg/day)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Risedronate (35 mg/week)
Number of subjects: 92
Study: 21519752

Group type: EXPERIMENTAL
Intervention: 5·10(8) cfu/day of L. plantarum CECT7315/7316 (low probiotic dose) (n = 13)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 5·10(9) cfu/day of the probiotic mixture (high probiotic dose) (n = 19)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (n = 15)
Number of subjects: 50
Study: 18356284

Group type: EXPERIMENTAL
Intervention: Mantram repetition (spiritual practice of repeating a sacred word/phrase)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Delayed-treatment control
Number of subjects: 33
Study: 16158402

Group type: EXPERIMENTAL
Intervention: Local influence measures for the Fine and Gray model for the subdistribution hazard
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Plot of local influence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Real data set from a randomized clinical trial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simulation study
Number of subjects: 0
Study: 12767365

Group type: EXPERIMENTAL
Intervention: Alternating therapy with mitomycin C (MMC) and bacillus Calmette‐Guerin (BCG)
Number of subjects: 304

Group type: COMPARATOR
Intervention: BCG monotherapy
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Alternating therapy with MMC and BCG
Number of subjects: 304
Study: 10711925

Group type: EXPERIMENTAL
Intervention: Circular stapled procedure
Number of subjects: 40

Group type: COMPARATOR
Intervention: Milligan-Morgan haemorrhoidectomy
Number of subjects: 40
Study: 8261970

Group type: EXPERIMENTAL
Intervention: Subhepatic drains (group A, n = 50 patients)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No drains (group B, n = 50 patients)
Number of subjects: 100
Study: 3910908

Group type: EXPERIMENTAL
Intervention: Immobilized streptokinase (streptodecase) administered to 37 patients
Number of subjects: 67

Group type: COMPARATOR
Intervention: Native thrombolytic drugs (streptokinase or urokinase) administered to 30 patients
Number of subjects: 67
Study: 31568306

Group type: EXPERIMENTAL
Intervention: Intraoperative navigation system
Number of subjects: 50

Group type: COMPARATOR
Intervention: No navigation system
Number of subjects: 50
Study: 29973224

Group type: EXPERIMENTAL
Intervention: Iron isomaltoside 1000 (IVFe) administered intravenously 1000 mg (maximum dose 20 mg/kg) 3 days before and after surgery
Number of subjects: 214

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Iron isomaltoside 1000 (IVFe)
Number of subjects: 214
Study: 28272175

Group type: EXPERIMENTAL
Intervention: Nebulized fluticasone 1,000 µg
Number of subjects: 147

Group type: COMPARATOR
Intervention: Normal saline solution (Control)
Number of subjects: 147
Study: 26232949

Group type: EXPERIMENTAL
Intervention: Child‐pedestrians Anticipate and Act Hazard Perception Training (CA(2)HPT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study: 23690356

Group type: EXPERIMENTAL
Intervention: Tetracaine hydrochloride-oxymetazoline hydrochloride nasal spray bilaterally with sham injection
Number of subjects: 45

Group type: COMPARATOR
Intervention: Intra-oral lidocaine-epinephrine injection with buffered saline nasal spray bilaterally
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 45
Study: 20949350

Group type: EXPERIMENTAL
Intervention: Risperidone (6 mg/day) plus sildenafil (75 mg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Risperidone (6 mg/day) plus placebo
Number of subjects: 40
Study: 18297438

Group type: EXPERIMENTAL
Intervention: BCAA granules (TK‐98) for 168 weeks
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 39
Study: 16571382

Group type: EXPERIMENTAL
Intervention: 5 mg daily risedronate for 3 years
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 5 mg daily risedronate for 5 years
Number of subjects: 7

Group type: COMPARATOR
Intervention: Comparison to healthy premenopausal women, n = 12
Number of subjects: 7
Study: 14649206

Group type: EXPERIMENTAL
Intervention: Ligustrazine (80 mg twice a day, intravenous perfusion for three weeks)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (Steroid, cyclophosphamide, losartan, and dipyridamole)
Number of subjects: 45
Study: 11811508

Group type: EXPERIMENTAL
Intervention: 3% potassium nitrate/0.2% sodium fluoride mouthwash
Number of subjects: 50

Group type: COMPARATOR
Intervention: 0.2% sodium fluoride control mouthwash
Number of subjects: 50
Study: 9839635

Group type: EXPERIMENTAL
Intervention: Coronary surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Angioplasty
Number of subjects: 0
Study: 8038977

Group type: EXPERIMENTAL
Intervention: Lidocaine pretreatment
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Propofol mixed with lidocaine (40 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Propofol at 4 degrees C
Number of subjects: 6

Group type: COMPARATOR
Intervention: Saline pretreatment
Number of subjects: 6
Study: 3193409

Group type: EXPERIMENTAL
Intervention: Cefoxitin plus doxycycline
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Ceftizoxime plus doxycycline
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Ceftizoxime alone
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Parenteral combination therapy (cefoxitin plus doxycycline or ceftizoxime plus doxycycline)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Monotherapy (ceftizoxime alone)
Number of subjects: 126
Study: 31505051

Group type: EXPERIMENTAL
Intervention: Multifactorial intervention with self-management education
Number of subjects: 189

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 189
Study: 27320133

Group type: EXPERIMENTAL
Intervention: Pre-notification leaflet (intervention group)
Number of subjects: 4314

Group type: COMPARATOR
Intervention: Trial recruitment pack (control group)
Number of subjects: 4314
Study: 26290088

Group type: EXPERIMENTAL
Intervention: E-Poly liner
Number of subjects: 61

Group type: COMPARATOR
Intervention: ArComXL liner (Control)
Number of subjects: 61
Study: 23406826

Group type: EXPERIMENTAL
Intervention: Boceprevir (BOC) added to pegylated interferon-α2b plus ribavirin (PR)
Number of subjects: 595

Group type: EXPERIMENTAL
Intervention: Boceprevir (BOC)
Number of subjects: 595

Group type: EXPERIMENTAL
Intervention: Low-dose ribavirin
Number of subjects: 595
Study: 22321499

Group type: EXPERIMENTAL
Intervention: Bleb morphology with microcysts
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Bleb morphology with non-vascular
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Age increase by 10 years
Number of subjects: 176
Study: 19850549

Group type: EXPERIMENTAL
Intervention: Health e-cards delivering depression information
Number of subjects: 348

Group type: COMPARATOR
Intervention: All conditions (including control)
Number of subjects: 348
Study: 16847734

Group type: EXPERIMENTAL
Intervention: HYBRID (problem-based learning oriented structured modules)
Number of subjects: 0

Group type: COMPARATOR
Intervention: TRAD (conventional teacher-centred course)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HYBRID
Number of subjects: 0

Group type: COMPARATOR
Intervention: TRAD
Number of subjects: 0
Study: 15014183

Group type: EXPERIMENTAL
Intervention: BIBN 4096 BS 2.5 mg
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: BIBN 4096 BS (all doses)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study: 11549929

Group type: EXPERIMENTAL
Intervention: Psychoeducational training
Number of subjects: 182

Group type: COMPARATOR
Intervention: Control group (no psychoeducational training)
Number of subjects: 182
Study: 9043563

Group type: EXPERIMENTAL
Intervention: Intervention 1: Placement of a brightly colored label in the medication drawer and on the cover of the nursing medication card flip-chart.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intervention 2: Placement of labels plus a five-minute structured patient-counseling session.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control phase: Existing pharmacy system with no patient-specific information on DNIs.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both interventions (label system and combined label-counseling system).
Number of subjects: 0
Study: 8172701

Group type: EXPERIMENTAL
Intervention: Proposed evaluation method for treatment of otitis media
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Statistical test of significance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgical treatment evaluation method
Number of subjects: 0
Study: 31697729

Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg.kg-1 body mass)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 30240030

Group type: EXPERIMENTAL
Intervention: Inference-to-alternates effect observed in a binary context
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Prior experience with similar inferences
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Indicative conditionals
Number of subjects: 9
Study: 26966823

Group type: EXPERIMENTAL
Intervention: Home-based calisthenic exercises
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Hospital-based calisthenic exercises
Number of subjects: 40
Study: 23796803

Group type: EXPERIMENTAL
Intervention: External focus (EF) of attention
Number of subjects: 42

Group type: COMPARATOR
Intervention: Internal focus (IF) of attention
Number of subjects: 42
Study: 22118603

Group type: EXPERIMENTAL
Intervention: Soflens Daily Disposable for Astigmatism (toric lenses)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Soflens Daily Disposable (spherical lenses)
Number of subjects: 41
Study: 19906075

Group type: EXPERIMENTAL
Intervention: Alitretinoin 30 mg once daily for 12-24 weeks
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Alitretinoin 10 mg once daily for 12-24 weeks
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study: 18678156

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) group A with cluster waves of 100 Hz
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) group B with continuous waves of 50 Hz
Number of subjects: 109

Group type: COMPARATOR
Intervention: Medication group (no EA)
Number of subjects: 109
Study: 15368546

Group type: EXPERIMENTAL
Intervention: ALL-DS
Number of subjects: 59

Group type: COMPARATOR
Intervention: ALL-NDS
Number of subjects: 59
Study: 12580681

Group type: EXPERIMENTAL
Intervention: Home intervention with weekly visits from 0 to 6 months and biweekly visits from 6 to 18 months
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group received brief monthly tracking visits
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 108
Study: 10539123

Group type: EXPERIMENTAL
Intervention: Intravenous ganciclovir (5 mg/kg/day)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Oral ganciclovir (3000 mg/day)
Number of subjects: 117
Study: 8768860

Group type: EXPERIMENTAL
Intervention: Combination recombinant human GH (rhGH; 0.34 mg, sc, twice daily) and rhIGF‐I (5.0 mg, sc, twice daily)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 142
Study: 1743712

Group type: EXPERIMENTAL
Intervention: Interferon alfa 2a 1.5 million units three times weekly for four weeks
Number of subjects: 154

Group type: COMPARATOR
Intervention: Podophyllin resin 25% applied to lesions twice weekly for up to six weeks
Number of subjects: 154
Study: 7103445

Group type: EXPERIMENTAL
Intervention: Ceforanide (30 mg/kg)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Cefamandole (30 mg/kg)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Ceforanide
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Cefamandole
Number of subjects: 26
Study: 31315868

Group type: EXPERIMENTAL
Intervention: Telehealth counselling intervention (12 sessions, 20-30 minutes each)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Text message check-ins and appointment reminders
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Clinical outcomes (plasma HIV RNA and CD4+ cell count)
Number of subjects: 80
Study: 29857783

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate/formoterol fumarate (Flutiform®; 100/10 µg b.i.d.)
Number of subjects: 512
Study: 27163503

Group type: EXPERIMENTAL
Intervention: 25 mg Opicapone (OPC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 50 mg Opicapone (OPC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 100 mg Opicapone (OPC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard-release 100/25 mg levodopa/carbidopa (LC) or levodopa/benserazide (LB) with Opicapone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 0
Study: 25434320

Group type: EXPERIMENTAL
Intervention: Drotaverine hydrochloride 80 mg tablet given thrice a day
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study: 22866682

Group type: EXPERIMENTAL
Intervention: Preview sentences condition
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Headings condition
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Five headings conditions during TTS presentation
Number of subjects: 2
Study: 20377423

Group type: EXPERIMENTAL
Intervention: RBV 2000 mg/day plus EPO 30,000 IU/week
Number of subjects: 149

Group type: COMPARATOR
Intervention: Weight-based RBV (1000-1200 mg/day)
Number of subjects: 149
Study: 18726926

Group type: EXPERIMENTAL
Intervention: Good outcome cases (psychotherapy with good therapeutic outcome)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Bad outcome cases (psychotherapy with bad therapeutic outcome)
Number of subjects: 2
Study: 16154480

Group type: COMPARATOR
Intervention: Valsartan 160 mg OD (V160)
Number of subjects: 774

Group type: EXPERIMENTAL
Intervention: Valsartan 160 mg OD plus Hydrochlorothiazide 12.5 mg OD (V160 + HCTZ12.5)
Number of subjects: 774

Group type: EXPERIMENTAL
Intervention: Valsartan 160 mg OD plus Hydrochlorothiazide 25 mg OD (V160 + HCTZ25)
Number of subjects: 774
Study: 12235507

Group type: EXPERIMENTAL
Intervention: Robotic assistant (EndoAssist)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Human assistant
Number of subjects: 93
Study: 9915392

Group type: EXPERIMENTAL
Intervention: Rigid fixation
Number of subjects: 125

Group type: COMPARATOR
Intervention: Wire osteosynthesis
Number of subjects: 125
Study: 7578641

Group type: EXPERIMENTAL
Intervention: Cued condition (instructional cues on measures of visual and semantic memory, executive function, and constructional ability)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Standard condition (performed the same neuropsychological measures without cues)
Number of subjects: 48
Study: 2265733

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion pump therapy (CSII)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional injection therapy (CT)
Number of subjects: 30
Study: 6778239

Group type: EXPERIMENTAL
Intervention: Ketotifen
Number of subjects: 36

Group type: COMPARATOR
Intervention: Disodium cromoglycate (DSCG)
Number of subjects: 36
Study: 30320641

Group type: EXPERIMENTAL
Intervention: Dexamethasone (8 mg) in group D
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Lidocaine (1.5 mg/kg) in group L
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Lidocaine (1.5 mg/kg) with Dexamethasone (8 mg) in group DL
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo (normal saline) in group NS
Number of subjects: 180
Study: 28644768

Group type: EXPERIMENTAL
Intervention: 100% feedback group (feedback on 3 movement reversals after each trial)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 14% feedback group (14% frequency according to a fading schedule)
Number of subjects: 42
Study: 27159624

Group type: EXPERIMENTAL
Intervention: Group DM (0.1 mg/kg dezocine + 0.05 mg/kg midazolam)
Number of subjects: 160

Group type: COMPARATOR
Intervention: All groups (including control)
Number of subjects: 160

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Groups D and DM (0.1 mg/kg dezocine)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Groups M and DM (0.05 mg/kg midazolam)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Group D (0.1 mg/kg dezocine)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Group M (0.05 mg/kg midazolam)
Number of subjects: 160
Study: 24702172

Group type: EXPERIMENTAL
Intervention: One-set resistance exercise trial (14-min)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Two-set resistance exercise trial (28-min)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Three-set resistance exercise trial (42-min)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Resting control trial
Number of subjects: 8
Study: 22520843

Group type: EXPERIMENTAL
Intervention: BCAA supplementation
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 27
Study: 20462437

Group type: EXPERIMENTAL
Intervention: Floseal
Number of subjects: 30

Group type: COMPARATOR
Intervention: ISC
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Floseal and ISC
Number of subjects: 30
Study: 18570058

Group type: EXPERIMENTAL
Intervention: 17-beta estradiol (E(2))
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 15804727

Group type: EXPERIMENTAL
Intervention: 0.45 mg of conjugated equine estrogens, 50 microg weekly transdermal estradiol (combined with cyclic oral, micronized progesterone, 200 mg for 12 days each month)
Number of subjects: 720

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 720
Study: 12600867

Group type: EXPERIMENTAL
Intervention: Multiple micronutrient (MM) supplementation, 6 days/week, containing 60 mg Fe and additional micronutrients (1-1.5 times the recommended dietary allowances)
Number of subjects: 873

Group type: COMPARATOR
Intervention: Iron-only supplementation, 6 days/week, containing 60 mg Fe
Number of subjects: 873